ClinicalTrials.gg
Drug

Trilaciclib clinical trials

Also written G1T28 and Cosela.

studies test it
35
open now
21
in phase 3
6
first study started
2015

How each study uses trilaciclib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the trilaciclib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
12 Feb 2021 · COSELA · NDA 214200 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Trilaciclib
23
CDK 4/6 inhibitor
5
Trilaciclib Injection
3
Trilaciclib plus chemotherapy
2

Brand

Cosela
8

Development codes

G1T28
11

Studies by the year they started

35 studies that test it; most in 2024 (11)

Studies that test trilaciclib, by start year
YearStudies
20152
20171
20217
20222
20236
202411
20252
20264

Who runs them

Industry 14 · Other 21

G1 Therapeutics, Inc. (9) · Jiangsu Simcere Pharmaceutical Co., Ltd. (3) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Sun Yat-sen University (3) · Pharmacosmos A/S (2) · Wake Forest University Health Sciences (1) · Henan Cancer Hospital (1) · Shandong Cancer Hospital and Institute (1)

Often tested with

Tested in the same studies.

Gemcitabine (2) · Cisplatin (2) · Pembrolizumab (1) · Carboplatin (1) · Eribulin (1) · Tislelizumab (1) · Antineoplastic Agents (1) · PM 01183 (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 9, 3 in phase 3

Studies that test trilaciclib, phase 3 first.

Studies

Open first, then newest update. How each study uses trilaciclib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 35

See all 35 studies that test trilaciclib →

Given beside what is tested · 8 — trilaciclib is usual care or a partner of the new treatment

Codes

What other systems call trilaciclib · ClinicalTrials.gg INT001357

  • MeSH (NLM) C000708352trilaciclibOne source NLM
  • UNII (FDA) U6072DO9XGTRILACICLIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2479690One source FDA
  • Wikidata Q105592965trilaciclibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C123281TrilaciclibOne source FDA
  • DrugBank DB15442One source Wikidata

Also registered as trilaciclib dihydrochloride (UNII 4BX07W725T · RxNorm 2479691).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.